标题
Recent advances of bispecific antibodies in solid tumors
作者
关键词
BsAb, Solid tumor, EpCAM, CEA, PSMA, HER family, Radioimmunotherapy
出版物
Journal of Hematology & Oncology
Volume 10, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-09-20
DOI
10.1186/s13045-017-0522-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity
- (2017) K Mølgaard et al. GENE THERAPY
- Chimeric antigen receptor T cells: a novel therapy for solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer
- (2017) Leslie Ann Caromile et al. Science Signaling
- PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer
- (2017) Leslie Ann Caromile et al. Science Signaling
- A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
- (2016) N. Haense et al. BMC CANCER
- Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity
- (2016) Jing Li et al. CANCER BIOLOGY & THERAPY
- A novel bispecific antibody, BiSS, with potent anti-cancer activities
- (2016) Bin Dong et al. CANCER BIOLOGY & THERAPY
- A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
- (2016) M. Bacac et al. CLINICAL CANCER RESEARCH
- In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing
- (2016) S. Lehmann et al. CLINICAL CANCER RESEARCH
- Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
- (2016) Michael Pishvaian et al. Clinical Colorectal Cancer
- Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions
- (2016) Matthias Klinger et al. IMMUNOLOGICAL REVIEWS
- High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
- (2016) Lorenzo Falchi et al. Journal of Hematology & Oncology
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial
- (2016) C. Bodet-Milin et al. JOURNAL OF NUCLEAR MEDICINE
- New and emerging targeted treatments in advanced non-small-cell lung cancer
- (2016) Fred R Hirsch et al. LANCET
- XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer
- (2016) Juergen M. Schanzer et al. mAbs
- Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
- (2016) Katharine D. Grugan et al. mAbs
- MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- (2016) G. Hernandez-Hoyos et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- (2016) Yong Jia et al. NATURE
- Radioimmunotherapy for Treatment of Acute Leukemia
- (2016) Caroline Bodet-Milin et al. SEMINARS IN NUCLEAR MEDICINE
- CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
- (2016) Marina Bacac et al. OncoImmunology
- A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity
- (2015) Zhiguo Chen et al. CANCER BIOLOGY & THERAPY
- A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3
- (2015) Morten Mau-Sørensen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
- (2015) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
- (2015) L. G. Lum et al. CLINICAL CANCER RESEARCH
- The coming of age of engineered multivalent antibodies
- (2015) Natalia Nuñez-Prado et al. DRUG DISCOVERY TODAY
- Development of a bispecific antibody tetramerized through hetero-associating peptides
- (2015) Tomohiro Osaki et al. FEBS Journal
- Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3)
- (2015) Marco Fossati et al. GYNECOLOGIC ONCOLOGY
- Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
- (2015) Francesca Ferrari et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells
- (2015) Dongmei Fan et al. Journal of Hematology & Oncology
- Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade
- (2015) Gaurav Goel et al. Journal of Hematology & Oncology
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Bispecific antibodies and their applications
- (2015) Gaowei Fan et al. Journal of Hematology & Oncology
- Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
- (2015) Gaurav Goel et al. Journal of Hematology & Oncology
- Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies
- (2015) Gerhard Zugmaier et al. MOLECULAR IMMUNOLOGY
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer
- (2015) YAN ZHOU et al. Molecular Medicine Reports
- Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo
- (2015) PAN MA et al. ONCOLOGY REPORTS
- Are BiTEs the “missing link” in cancer therapy?
- (2015) Carter M Suryadevara et al. OncoImmunology
- A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells
- (2015) Benjamin J. Solomon et al. PLoS One
- Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
- (2014) Jayakumar S. Poovassery et al. INTERNATIONAL JOURNAL OF CANCER
- CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
- (2014) Michael D Oberst et al. mAbs
- Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications
- (2014) Marta Compte et al. OncoImmunology
- Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
- (2013) Ian M Zitron et al. BMC CANCER
- Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells
- (2013) Daniel A. Vallera et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression
- (2013) Pengfei Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab
- (2013) D. Goere et al. CANCER RESEARCH
- Targeting T cells to tumor cells using bispecific antibodies
- (2013) Stanley R Frankel et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Advances in bispecific biotherapeutics for the treatment of cancer
- (2012) Chad May et al. BIOCHEMICAL PHARMACOLOGY
- Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody
- (2012) Shuhui Wang et al. CANCER LETTERS
- New Gene-Immunotherapy Combining TRAIL-Lymphocytes and EpCAMxCD3 Bispecific Antibody for Tumor Targeting
- (2012) A. Groth et al. CLINICAL CANCER RESEARCH
- Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis
- (2012) Matthew R. Dallas et al. FASEB JOURNAL
- Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells
- (2012) Volker Baum et al. Immunotherapy
- Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement
- (2012) P.-Y. Salaun et al. JOURNAL OF NUCLEAR MEDICINE
- Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts
- (2012) Ines Martin-Padura et al. LABORATORY INVESTIGATION
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
- (2012) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Immunology beats cancer: a blueprint for successful translation
- (2012) Drew M Pardoll NATURE IMMUNOLOGY
- The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
- (2012) Li Peng et al. PLoS One
- A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance
- (2012) P. J. Yazaki et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Immuno-targeting of pancreatic cancer stem cells
- (2012) Michele Cioffi et al. OncoImmunology
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
- (2011) M. Cioffi et al. CLINICAL CANCER RESEARCH
- Targeting ErbB Receptors in High-Grade Glioma
- (2011) Sabina Berezowska et al. CURRENT PHARMACEUTICAL DESIGN
- Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab′)2 antibody
- (2010) Frits Aarts et al. CANCER
- Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action
- (2010) Franziska Hirschhaeuser et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy
- (2010) Sabrina C. Hoffmann et al. INTERNATIONAL JOURNAL OF CANCER
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- EGFR Antibodies in Colorectal Cancer: Where Do They Belong?
- (2010) Axel Grothey JOURNAL OF CLINICAL ONCOLOGY
- Pretargeted Immuno–Positron Emission Tomography Imaging of Carcinoembryonic Antigen–Expressing Tumors with a Bispecific Antibody and a68Ga- and18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts
- (2010) Rafke Schoffelen et al. MOLECULAR CANCER THERAPEUTICS
- Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
- (2010) Ines Herrmann et al. PLoS One
- T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
- (2010) Ralf Lutterbuese et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody
- (2010) Kerstin Fortmüller et al. PROSTATE
- Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy
- (2010) Robert M. Sharkey et al. SEMINARS IN NUCLEAR MEDICINE
- Cetuximab, its clinical use and future perspectives
- (2009) Fernando Rivera et al. ANTI-CANCER DRUGS
- Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
- (2009) T Osada et al. BRITISH JOURNAL OF CANCER
- The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
- (2009) M. Jager et al. CANCER RESEARCH
- The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
- (2009) M. Munz et al. CANCER RESEARCH
- The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor
- (2009) Xiao-Lan Xu et al. CARCINOGENESIS
- Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
- (2009) Cornelia Haas et al. IMMUNOBIOLOGY
- Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma
- (2009) Alexei V. Salnikov et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release
- (2009) Maria Amann et al. JOURNAL OF IMMUNOTHERAPY
- Target-dependent T-cell Activation by Coligation With a PSMA×CD3 Diabody Induces Lysis of Prostate Cancer Cells
- (2009) Patrick Bühler et al. JOURNAL OF IMMUNOTHERAPY
- Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
- (2009) Ralf Lutterbuese et al. JOURNAL OF IMMUNOTHERAPY
- Nuclear signalling by tumour-associated antigen EpCAM
- (2009) Dorothea Maetzel et al. NATURE CELL BIOLOGY
- Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
- (2009) B. Schoeberl et al. Science Signaling
- EpCAM Is Involved in Maintenance of the Murine Embryonic Stem Cell Phenotype
- (2009) Bárbara González et al. STEM CELLS
- Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
- (2008) Maria Amann et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
- (2008) M. Amann et al. CANCER RESEARCH
- Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody
- (2008) Shoshana Morecki et al. EXPERIMENTAL HEMATOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model
- (2008) Robert M. Sharkey et al. RADIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search